Shimizu E, Kamei T, Kimura K, Mukai J, Nakamura Y, Kunishige E, Fukuta K, Tani K, Sone S, Ogura T
3rd Dept. of Internal Medicine, Tokushima University School of Medicine.
Gan To Kagaku Ryoho. 1989 Dec;16(12):3719-23.
Fifteen patients (six patients with adenocarcinoma, seven patients with squamous cell carcinoma, and two patients with large cell carcinoma) with advanced non-small cell lung cancer (NSCLC) were evaluable for mitomycin C (MMC; 8 mg/m2 day 1, 8, every 3-4 weeks) plus cisplatin (CDDP; 80 mg/m2 day 1, every 3-4 weeks). Ten patients had had prior chemotherapy. Among 15 evaluable patients, no patient achieved complete response, and two patients showed partial response. The response rate of MMC plus CDDP against NSCLC was 13.3%. Toxic effects included anorexia (80%), nausea and vomiting (67%), leukopenia (53%), anemia (47%), nephrotoxicity (47%), thrombopenia (27%), liver injury (27%), and fever (7%). These toxic effects were reversible and manageable. The combination of MMC and CDDP appears to be valuable regimen against advanced NSCLC.
15例晚期非小细胞肺癌（NSCLC）患者（6例腺癌、7例鳞状细胞癌和2例大细胞癌）可评估丝裂霉素C（MMC；8mg/m²，第1天，每3 - 4周8mg）联合顺铂（CDDP；80mg/m²，第1天，每3 - 4周）的疗效。10例患者曾接受过化疗。在15例可评估患者中，无患者达到完全缓解，2例患者显示部分缓解。MMC联合CDDP治疗NSCLC的缓解率为13.3%。毒性反应包括厌食（80%）、恶心和呕吐（67%）、白细胞减少（53%）、贫血（47%）、肾毒性（47%）、血小板减少（27%）、肝损伤（27%）和发热（7%）。这些毒性反应是可逆的且可控制。MMC与CDDP联合似乎是治疗晚期NSCLC的有效方案。
